Huntsman Ronald Kirk 4
4 · Vivos Therapeutics, Inc. · Filed Feb 28, 2022
Insider Transaction Report
Form 4
Huntsman Ronald Kirk
DirectorChief Executive Officer10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2022-02-25$3.27/sh+125,000$408,750→ 125,000 totalExercise: $3.27Exp: 2027-02-25→ Common Stock (125,000 underlying)
Footnotes (1)
- [F1]125,000 stock options granted on February 25, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through February 25, 2026.